Abstract |
A recombinant anti-CD25 immunotoxin, LMB-2, has shown clinical efficacy in hairy cell leukemia and T-cell neoplasms. Its activity in B-cell chronic lymphocytic leukemia (B-CLL) is inferior but might be improved if B-CLL cells expressed higher numbers of CD25 binding sites. It was recently reported that DSP30, a phosphorothioate CpG- oligodeoxynucleotide ( CpG-ODN) induces immunogenicity of B-CLL cells by up-regulation of CD25 and other antigens. The present study investigated the antitumor activity of LMB-2 in the presence of DSP30. To this end, B-CLL cells from peripheral blood of patients were isolated immunomagnetically to more than 98% purity. Incubation with DSP30 for 48 hours augmented CD25 expression in 14 of 15 B-CLL samples, as assessed by flow cytometry. DSP30 increased LMB-2 cytotoxicity dose dependently whereas a control ODN with no CpG motif did not. LMB-2 displayed no antitumor cell activity in the absence of CpG-ODN as determined colorimetrically with an (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. In contrast, B-CLL growth was inhibited in 12 of 13 samples with 50% inhibition concentrations (IC(50)) in the range of LMB-2 plasma levels achieved in clinical studies. Two samples were not evaluable because of spontaneous B-CLL cell death in the presence of DSP30. Control experiments with an immunotoxin that does not recognize hematopoietic cells, and an anti-CD22 immunotoxin, confirmed that sensitization to LMB-2 was specifically due to up-regulation of CD25. LMB-2 was much less toxic to normal B and T lymphocytes compared with B-CLL cells. In summary, immunostimulatory CpG-ODNs efficiently sensitize B-CLL cells to a recombinant immunotoxin by modulation of its target. This new treatment strategy deserves further attention.
|
Authors | Thomas Decker, Susanne Hipp, Robert J Kreitman, Ira Pastan, Christian Peschel, Thomas Licht |
Journal | Blood
(Blood)
Vol. 99
Issue 4
Pg. 1320-6
(Feb 15 2002)
ISSN: 0006-4971 [Print] United States |
PMID | 11830482
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adjuvants, Immunologic
- Antibodies, Monoclonal
- Antineoplastic Agents
- B3(Fv)-PE38KDEL recombinant immunotoxin
- CPG-oligonucleotide
- Exotoxins
- Immunotoxins
- Oligodeoxyribonucleotides
- Receptors, Interleukin-2
- Recombinant Proteins
- Thionucleotides
|
Topics |
- Adjuvants, Immunologic
(pharmacology, therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Drug Synergism
- Drug Therapy, Combination
- Exotoxins
- Female
- Humans
- Immunotoxins
(pharmacology, therapeutic use)
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy, pathology)
- Male
- Middle Aged
- Oligodeoxyribonucleotides
(pharmacology, therapeutic use)
- Receptors, Interleukin-2
(biosynthesis, drug effects, immunology)
- Recombinant Proteins
(pharmacology, therapeutic use)
- Thionucleotides
(pharmacology, therapeutic use)
- Tumor Cells, Cultured
(drug effects)
- Up-Regulation
(drug effects)
|